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Abbreviations  
BV Brilliant Violet 
CD Cluster of Differentiation 
CLEC C-type lectin receptor 
EDTA  Ethylenediaminetetraacetic acid 
FCS Fetal calf serum 
FSC-A Forward Scatter 
HBSS Hank’s Balanced Salt Solution 
IFN Interferon 
LPS Lipopolyscaccharide 
PMA Phorbol 12-myristate 13-acetate 
Siglec Sialic acid-binding immunoglobulin-type lectins 
SSC-A Side Scatter - Area 
SSC-W  Side Scatter - Width 
TIM T cell immunoglobulin and mucin domain containing 
TNF Tumor necrosis factor 
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Abstract  
Macrophages are key in orchestrating immune responses to micro-environmental stimuli, 
sensed by a complex set of surface receptors.  The human cell line THP-1 has a monocytic 
phenotype, including the ability to differentiate into macrophages, providing a tractable, 
standardised surrogate for human monocyte-derived macrophages.  Here we assessed the 
expression of 49 surface markers including Fc, complement, C-type lectin and scavenger 
receptors; TIMs; Siglecs; and co-stimulatory molecules by flow cytometry on both THP-1 
monocytes and macrophages and following macrophage activation with seven standard 
conditioning/polarizing stimuli.  Of the 34 surface markers detected on macrophages, 18 
altered expression levels on activation.  From these, expression of 9 surface markers were 
consistently altered by all conditioning regimens, while 9 were specific to individual 
polarizing stimuli.  This study provides a resource for the study of macrophages and 
highlights that macrophage polarization states share much in common and the differences 
do not easily fit a simple classification system.   
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1. Introduction 
Monocytes and macrophages play a key role in innate immune responses, from pathogen 
recognition, phagocytosis, signalling via cytokines and chemokines to tissue repair and 
remodelling [1]. Resident tissue macrophages sense injury or infection and recruit 
circulating leukocytes. Infiltrating monocytes/macrophages respond to micro-environmental 
signals by engaging various activation programs and mature into sub-populations that 
restore tissue homeostasis by destroying microorganisms or promoting healing.  The known 
range of macrophage activation states, and the cues that induce polarization, continue to 
expand, but two broad types of macrophage activation in vitro have been characterized in 
detail: classical or M1 macrophages and alternative or M2 macrophages. M1 activated 
macrophages are induced by a combination of IFN- and pro-inflammatory stimuli (such as 
LPS or TNF-) and have anti-microbial and cytotoxic properties, whereas M2 activated 
macrophages are anti-inflammatory and reparative. M2 macrophages have been further 
sub-divided, using IL-4 to induce M2a macrophages, immune complexes and IL-1R agonists 
for M2b and IL-10, TGF- or glucocorticoids for M2c [2].  However this classification system 
is now considered to be an oversimplification of a spectrum of activation states and 
responses observed in vivo [3].  Studies in mice have demonstrated a huge degree of 
diversity in tissue macrophages under both physiological conditions and disease contexts, 
which are likely to be similar in man.  Macrophage phenotypes not addressed by the M1/M2 
classification system have also been delineated.  For example Mhem phenotype 
macrophages are induced by heme or hemoglobin, resulting in enhanced iron handling and 
increased expression of CD163, a scavenger receptor for hemoglobin and HO-1 [4]. Mhem 
macrophages are found in areas of plaque hemorrhage [4, 5] and the relative abundance of 
these macrophage subsets is a better indicator of plaque progression and stability than the 
total number of lesion macrophages [6]. 
 
Whilst the stimuli used to study macrophage polarization in vitro have been well defined, to 
date no single specific phenotypic markers have been identified to characterize macrophage 
subtypes.  Instead changes in groups of markers have been demonstrated, mostly in mice, 
which do not necessarily translate directly to humans [7].  Work in primary human 
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macrophages is hampered by difficulties in obtaining primary material, including isolating 
sufficient quantities for experimentation and variability between donors.  The human 
monocytic cell line THP-1 is widely used for the study of both monocytes and macrophages.  
THP-1 macrophages provide several advantages over tissue resident or peripheral blood 
mononuclear cell (PBMC) derived macrophages: ease of access, long-term storage, faster 
growth rates, relative homogeneity with the same genetic background and the absence of 
contaminating cells [8].  Published studies have analyzed responses to polarizing stimulation 
by THP-1 macrophages using transcriptomic or proteomic analyses [9, 10].  However, the 
range of phenotypic surface markers characterizing THP-1 macrophages has not been 
reported in detail. This would be invaluable to predict the responses of THP-1 cells to 
external stimuli and whether they are a representative surrogate for the more complex in 
vivo primary human macrophages. 
 
To address this gap in knowledge and as a baseline to compare with tissue and blood 
monocyte derived macrophages, this study used flow cytometry to examine the surface 
expression of a wide range of important functional markers on both monocyte and 
macrophage THP-1 cells.  These included Sialic acid-binding immunoglobulin-type lectins 
(Siglecs) which distinguish self from non-self;   complement and Fc-gamma receptors that 
recognize opsonized pathogens; scavenger receptors that clear cell debris; T cell 
immunoglobulin and mucin domain containing receptors (TIM) that bind phosphatidylserine 
on apoptotic cells; C-type lectin receptors which have a range of functions including cell 
adhesion, immune response to pathogens and apoptosis; co-stimulatory molecules 
important in antigen presentation  and commonly used as markers of monocytes and 
macrophages  Changes in expression of these markers resulting from culturing THP-1 
macrophages with widely used polarizing stimuli (LPS, IFN-, IL-4, IL-1, immune complex, IL-
10 and hemoglobin:haptoglobin complex) were also determined.  The findings allow the 
examination of an intricate system of changes within a homogeneous cell line and a basis 
for predicting the suitability of THP-1 cells as a surrogate for primary human 
monocytes/macrophages.  They also provide an extensive resource for investigators 
interested in studying the immune receptors or conditioning regimens presented for the 
study of monocyte and macrophage biology.   
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2. Materials and Methods 
2.1 Cells 
The THP-1 cells were purchased from Sigma Aldrich and maintained in a humidified 
incubator at 37oC with 5% CO2 in RPMI 1640 (Gibco) supplemented with 20% heat-
inactivated FCS (VWR) and 100 units/mL penicillin, 100 µg/mL streptomycin and 292 µg/mL 
L-glutamine (Gibco).  Cells were seeded at 5 x 105 cells/mL in 5 mL into a 75 cm3  tissue 
culture flask, then differentiated into (M0) macrophage-like cells by stimulation with PMA 1 
ng/mL (Sigma Aldrich) for four days followed by 48 hr without PMA.  To alter the phenotype, 
macrophages were stimulated after 24 hrs rest without PMA for 24 hrs with LPS (10 ng/mL; 
Sigma Aldrich), LPS and IFN- (20 ng/mL; Miltenyi Biotec), IL-4 (20 ng/mL; Miltenyi Biotec), 
IL-1 (20 ng/mL; Miltenyi Biotec) and immune complex (rabbit Anti-OVA 100 µg/mL bound 
OVA 10 µg/mL; Sigma Aldrich), IL-10 (20 ng/mL; Miltenyi Biotec) or hemoglobin:haptoglobin 
complex (1:1, 100 nM; Sigma Aldrich).   
 
2.2 Flow Cytometry (Staining) 
THP-1 monocytes were washed with ice-cold HBSS, 2 mM EDTA, 5% FCS.  THP-1 
macrophages were lifted from the plastic with ice-cold HBSS, 2 mM EDTA, 5% FCS and 
gentle scraping.  Non-specific staining was blocked using Fc block (Human TruStain FcX; 
BioLegend) incubated at room temperature for 10 minutes.  Cells were then split between 
master-mixes of antibody and isotype panels and incubated for 30 mins at 4oC in the dark.  
Panel 1: Dectin 1 VioBright FITC; CD69 Brilliant Violet (BV)650; CD207 VioBlue; CLEC12A 
PerCP-Cy5.5; CLEC4A PE-Vio770; KLRG1 PE-Vio615; Dectin 2 PE; CD45 VioGreen.  Panel 2: 
ASGPR1 VioBright FITC; HLA-DR BV650; CLEC9A VioBlue; CD1a PerCP-Cy5.5; CLEC13A PE-
Vio770; CD303 PE/Dazzle 594; CLEC10A PE; CD45 VioGreen.  Panel 3: CD329 VioBright FITC; 
CD14 BV650; CD328 VioBlue; Siglec 8 PerCP; CD169 PE-Vio770; CD33 PE-CF594; Siglec 10 PE; 
CD45 VioGreen.  Panel 4: CD327 AF488; CD11b VioBlue; CD16 PerCP-Vio770; CD32 PE-Cy7; 
CD64 PE/Dazzle 594; CLEC4D PE; CD45 VioGreen.  Panel 5: CD204 VioBright FITC; TIM-3 
BV650; CD59 BV421; CD36 PerCP; CD55 PerCP-Cy5.5; TIM-1 PE-Vio770; CD163 PE/Dazzle 
594; TIM-4 PE; CD45 VioGreen.  Panel 6: SIRP FITC; CD86 BV650; CD80 BV421; CD209 
PerCP-Cy5.5; SIRP PE-Vio770; CD206 PE/Dazzle 594; CD205 PE; CD45 VioGreen.  Panel 7: 
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CD93 FITC; CD11c BV650; Mertk BV421; CD35 PerCPVio770; CD170 PE-Vio770; CD13 
PE/Dazzle 594; CD299 PE; CD45 VioGreen.  Further details of isotype controls and antibody 
clones and sources are given in the MiFlowCyt Section of the Appendices (A.1).  After 
staining, cells were washed and fixed for analysis (Cytofix; BD Biosciences).  Cells were 
acquired on a BD LSRFortessa within 48 hrs and a minimum of 20,000 CD45+ cells (mean 
94,000) were acquired for each test.   
 
2.3 Flow Cytometry (Analysis) 
Flow cytometric data were analyzed by FlowJoX software, details can be seen in A.1.  
Monocytes and macrophages were gated by forward scatter – area (FSC-A) and side scatter 
– area (SSC-A), then single cells by SSC-A and side scatter-width (SSC-W).  GeoMean was 
calculated for the single cells, then normalized by subtracting the isotype GeoMean value 
for the matching cell type.  Markers were deemed to be expressed if 2 out of the 4 samples 
tested had a normalized GeoMean greater than 100.   
 
2.3 Statistics 
Results are presented as median ± interquartile range.  Statistical significance was tested 
using Mann-Whitney tests for all comparisons.  Graphing and statistical analyses were 
performed using Prism 5 (GraphPad Software, Inc.). 
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3. Results  
3.1 THP-1 monocytes: surface marker expression 
The expression of a wide range of monocyte/macrophage phenotypic and functional 
markers was assessed. These included those already well known to be expressed on the 
THP-1 cell surface, such as CD13 and CD14, and some that were previously believed not to 
be expressed, such as CD1a [11-13].  Figure 1 shows the histogram plots for each marker 
analyzed on THP-1 monocytes, expression assessed by comparison with matched isotype 
control.  Of the Siglecs tested, THP-1 monocytes expressed CD169 (Siglec 1), CD33 (Sigelec 
3) and CD170 (Siglec 5) but not CD327 (Siglec 6), CD328 (Siglec 7), Siglec 8, CD329 (Siglec 9) 
or Siglec 10.  THP-1 monocytes did not express the complement receptors CD35, CD55 and 
CD59, nor the scavenger receptors CD36, CD163 and CD204.  The Fc receptors CD32 and 
CD64 were expressed by THP-1 monocytes, but CD16 was not.  Of the TIM receptors tested, 
THP-1 monocytes expressed TIM-1, but not TIM-3 or TIM-4.  Numerous C-type lectin 
receptors were assessed and THP-1 monocytes showed the presence of only CD299, 
CLEC10A, CLEC13A and CD205 on the surface.  SIRP and SIRP were also expressed, along 
with CD13 and HLA-DR.  THP-1 monocytes did not demonstrate surface expression of CD80, 
CD86, CD11b, CD11c, CD14, Mertk or CD1a (Figure 1).   
 
3.2 Differentiation changes THP-1 size and granularity 
Differentiation from monocyte to macrophage is associated with an increase in size, 
granularity and auto-fluorescence [14].  To check that the PMA-mediated differentiation of 
THP-1 monocytes to macrophages was successful, the FSC-A and SSC-A of THP-1 monocytes 
and macrophages were compared, (Figure 2).  In line with other [12], there were significant 
increases in both size (FSC-A) and granularity (SSC-A) and a slight increase in auto-
fluorescence in every channel recorded.  
       
3.3 THP-1 macrophage surface marker expression 
The surface markers expressed by PMA differentiated macrophages that had been rested 
for 48 hrs (to ensure any stimulation induced had returned to baseline), were analyzed 
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(Figure 3).  Like the monocytes from which they were differentiated, THP-1 macrophages 
demonstrated specific positivity for CD169, CD33, CD170 as well as Siglec 8, CD329 and 
Siglec 10.  In contrast to the monocytes, THP-1 macrophages exhibited expression of CD35, 
CD55 and CD59, along with the scavenger receptors CD36, CD163 and CD204, reflecting a 
more mature nature.  The THP-1 macrophages, similarly to their monocytic equivalent, 
expressed CD32 and CD64, but not CD16.  THP-1 macrophages expressed TIM-1, but not 
TIM-4, on their surface, but, unlike monocytes, also expressed TIM-3.  Macrophages 
demonstrated expression of a greater abundance of C-type lectin receptors than 
monocytes, expressing CLEC4A, CLEC4D, CD299, CLEC10A, CLEC13A, CD205 and KLRG1.  As 
with monocytes, macrophages expressed SIRP, SIRP and CD13, but not CD80 and CD1a.  
Unlike monocytes, they also expressed CD11b, CD11c, CD14, CD86 and Mertk, with an 
absence of HLA-DR (Figure 3).   
 
3.4 Comparison of the level of surface marker expression by THP-1 monocytes versus THP-
1 macrophages 
Of the markers expressed by both monocytes and macrophages, macrophages displayed 
significantly greater expression of CD33, CD170, TIM-1, CD299, CLEC10A, CLEC13A, SIRP 
and CD13, but significantly lower expression of CD32 and CD205 (Figure 4).  There was no 
difference in the expression of CD169, CD64 and SIRP following PMA induced 
differentiation into macrophages.         
 
3.5 THP-1 macrophage extracellular marker expression after phenotype biasing 
The expression of many macrophage markers is known to change in response to stimuli, 
generally associated with an alteration of role, notably, for example, inflammatory or anti-
inflammatory.  We chose stimuli to reflect commonly studied macrophage phenotypes [2].  
We also investigated modifications resulting from exposure to hemoglobin:haptoglobin 
complexes, which are associated with the development of a macrophage phenotype 
important in the progression of atherosclerosis in vivo [4].   
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It was determined whether addition of polarizing stimuli resulted in a change of morphology 
(Figure 5).  The addition of LPS or LPS/IFN- produced a decrease in the FSC-A of the 
macrophages, indicating a decrease in cell size.  The SSC-A, indicating granularity, was 
increased by the addition of IL-10.     
      
In response to these stimuli, the expression of many markers altered (Figure 6).  However, 
there was no statistically significant change of expression of CD170, Siglec 8, Siglec 10, 
CD35, CD55, CD59, CD163, CD204, CD32, TIM-1, CLEC4D, CD299, CLEC13A, SIRP, CD11c, or 
CD13 following 24 hr culturing with any of the stimuli tested compared with M0.  When 
comparing the polarizing stimuli (except hemoglobin:haptoglobin complexes, which did not 
alter the expression of any marker tested) an unexpected pattern of changes emerged.  Of 
the 18 markers that changed in a statistically significant fashion with any of the conditioning 
regimens, nine altered expression specifically in response to one or two of the regimens 
(CD36, CLEC4A, CLEC10A, KLRG1, SIRP, CD86, MertkHLA-DR and CD64).  The other nine, 
however, changed expression compared to M0 in the same direction and similar magnitude 
irrespective of the stimuli.  The markers CD33, CD329, TIM-3, CD205, CD11b and CD14 all 
decreased in expression relative to M0 and CD169, CD209 and CD80 all increased expression 
relative to M0.  CD64 is somewhat different in that all the stimuli except IFN-/LPS resulted 
in a decrease in expression compared to M0.   
 
The addition of LPS to THP-1 macrophages resulted in a statistically significant increase in 
the expression of CD169, CLEC4A and CLEC10A and a decrease in CD33, CD329, CD64, TIM-
3, CD205, CD11b and CD14.  Addition of IFN- in combination with LPS resulted in the same 
alterations in expression as LPS induced, except in the case of CD64, which did not 
significantly change compared to no treatment.  KLRG1 increased significantly and SIRP 
demonstrated decreased expression.  IL-4 addition to THP-1 cultures led to an increase in 
CD169 and CD86.  A significant decrease in expression of CD33, CD329, CD64, TIM-3, CD205, 
SIRP, CD14 and Mertk was elicited by the addition of IL-4.  Immune complexes in 
combination with IL-1 also increased the expression of CD169 and decreased CD33, CD329, 
CD64, TIM-3, CD205, CD11b, CD14 and Mertk expression.  When added to macrophages, IL-
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10 increased CD169 expression and decreased that of CD33, CD329, CD36, CD64, TIM-3, 
CD205 and CD14.  
 
The C-type lectin receptor CD209 was deemed not to be expressed by THP-1 macrophages 
at initial observation.  However, the addition of LPS, LPS/IFN- or IL-4 resulted in expression 
of CD209 above the pre-defined threshold.  The co-stimulatory molecule CD80 showed no 
detectable expression by THP-1 macrophages, but LPS, LPS/IFN-, IL-4, IC/IL-1 and IL-10 all 
increased expression to above the pre-determined threshold.   Similarly, HLA-DR expression 
was not detectable by resting macrophages, but addition of IFN- and LPS resulted in a 
significant increase.   
 
The Geomeans for all markers and conditions investigated are presented in Appendices Fig 
B.1 for reference.   
 
The markers CLEC4A and CLEC10A have a bimodal distribution as shown in Figure 3.  The 
histograms for markers TIM-1, CD204, CLEC13A and CD14 suggest that only a portion of the 
population express the marker.  Figure 7 shows the percentage positive of these markers 
following phenotype biasing.  Similarly to the normalised GeoMean, there is no statistically 
significant difference in percentage TIM-1 and CLEC13A positive cells following phenotype 
biasing.  Also similar to GeoMean, there is a statistically significant decrease in CD14 
percentage positive cells after all phenotype biasing stimuli except hemoglobin: haptoglobin 
complex.  The percentage CLEC10A positive cells increased significantly with LPS, LPS/IFN-, 
and, unlike GeoMean, IL-4.    The percentage of cells positive for CLEC4A significantly 
increased in response to LPS, LPS/IFN-, IL-4 and IL-10.  The presence of two markers in the 
same panel allows a comparison of the expression by cells positive for either of both of the 
markers.  CLEC10A and CLEC13A are on the same panel, on average 67% of CLEC10A+ cells 
are also positive for CLEC13A, and conversely 68% of CLEC13A+ cells are also positive for 
CLEC10A.  TIM-1 and CD204 are also on the same panel, 72% of CD204+ cells are positive for 
TIM-1, and 83% of TIM-1+ cells are positive for CD204.   
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4. Discussion 
Macrophages play an important role in immune responses by sensing and responding to 
their environment to either drive or resolve inflammation.  Key to this function are 
molecular signatures expressed on their cell surfaces.  To provide a resource for the study of 
macrophage biology and to establish patterns of expression in a homogenous cell type, we 
assessed the surface expression of a wide range of receptors on the human THP-1 
monocytic cell line and their PMA differentiated macrophages, and determined changes in 
expression following activation by well described conditioning regimens.  We found that 
macrophages, as expected given their physiological role, expressed a greater range of 
surface markers than monocytes.    Much is made in the literature of the difference 
between M1-like and M2-like phenotypes, but we found all of the conditioning regimens, 
with the exception of hemoglobin:haptoglobin, tended to effect similar changes, with some 
exceptions discussed below.  These similarities suggest that many of the polarizing stimuli 
induce common pathways rather than distinct differentiation programs.           
 
Complex mixtures of glycans are expressed on the surfaces of all cells, both host and 
microbial, and their recognition is important in maintaining homeostasis and fighting 
disease.  Sialic acids are prominent on human cells and are recognized by Siglecs, a series of 
inhibitory type 1 membrane proteins.  We analyzed the expression of CD169 (Siglec 1), CD33 
(Siglec 3), CD170 (Siglec 5), CD327 (Siglec 6), CD328 (Siglec 7), Siglec 8, CD329 (Siglec 9) and 
Siglec 10.  We found that CD169 was present on the surface of both THP-1 monocytes and 
macrophages and that stimulation with all the phenotype altering conditions, except 
hemoglobin:haptoglobin complexes, significantly increased its expression.  CD169 has been 
shown to be expressed on circulating monocytes and is important in inflammatory 
conditions such as rheumatoid arthritis and multiple sclerosis, where CD169 expression is 
higher in patients than healthy controls [15, 16].  Little is known about the effects of 
phenotype biasing on the expression of CD169 by macrophages [17].   
 
All other Siglecs tested were from the CD33-related Siglec family (CD33, CD170, CD327, 
CD328, Siglec 8, CD329, Siglec 10).  Our study indicated that THP-1 monocytes expressed 
only CD169, CD33 and CD170.  It has been previously shown that monocytes isolated from 
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peripheral blood express CD33, CD170, CD328, CD329 and Siglec 10 but not Siglec 8 [18].  
Therefore THP-1 monocytes have a reduced expression profile of Siglecs compared to 
primary circulating monocytes.  This should be considered in studies determining the 
influences on Siglecs when using THP-1 monocytes as a surrogate to primary cells. 
 
The study presented here showed expression of CD33, CD170, Siglec 8, CD329 and Siglec 10, 
but not CD327 or CD328 by THP-1 macrophages.  The expression of Siglecs on human 
monocyte derived M-CSF and GM-CSF differentiated macrophages has previously been 
reported, with CD170, CD328 and CD329 basally expressed and Siglec 8 and Siglec 10 
expressed after GM-CSF differentiation [18].  Gene expression by qPCR showed that CD328 
and CD329 were induced by M-CSF or GM-CSF driven differentiation, but expression of 
CD170, Siglec 10 and CD33 decreased during differentiation [19].  CD329 mRNA was 
unaltered by treatment with LPS/IFN- or IL-4; CD328 decreased with LPS /IFN-; Siglec 10 
increased with IL-4 and CD33 and CD170 decreased with both LPS/IFN-and IL-4 [19].  This 
indicates that THP-1 macrophages resemble macrophages differentiated from circulating 
blood monocytes with GM-CSF.  We found decreased CD33 expression after all phenotype 
biasing stimuli, except hemoglobin:haptoglobin complexes, in line with Higuchi et al. [19].  
However results from THP-1 macrophages contrasted with blood monocyte derived 
macrophage phenotypes [19], in that CD170, Siglec 8 and Siglec 10 were unaltered and 
CD329 expression decreased with all phenotype biasing stimuli except 
hemoglobin:haptoglobin.   
 
The complement receptors we tested, CD35, CD55 and CD59, were not expressed on THP-1 
monocytes, but were on THP-1 macrophages, although remained unaltered by the stimuli 
we used.  Few studies have investigated complement receptors on THP-1 cells, but our 
results are consistent with those showing an increase in receptor expression following 
differentiation [20]. This reflects the greater role of macrophages as compared to 
monocytes in clearing complement opsonised pathogens. 
 
The expression of the scavenger receptors CD36, CD163 and CD204 by THP-1 macrophages 
but not monocytes, as shown here, is consistent with multiple studies.  CD36 in particular is 
often used as a marker of THP-1 differentiation [21].  The results shown here contrast with 
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studies demonstrating CD163 and CD204 as M2 markers (as induced by IL-4) [22, 23].  
Moreover CD163 has been shown to be a main receptor upregulated following stimulation 
by the hemoglobin:haptoglobin complex. Here we showed no statistically significant 
alteration in CD163 and CD204 expression with any conditioning regimen.  This discrepancy 
might be due to differences in culture times: we used 24hrs, others 72hrs [22].    
 
It is well established that THP-1 monocytes lack CD16, an observation confirmed here, we 
also confirmed previous reports that THP-1 monocytes expressed CD32 and CD64 [24] and 
expression is lower after differentiation to macrophages [25].  Fc gamma receptor 
expression on THP-1 macrophages after phenotype altering stimuli has not previously been 
reported.  However, studies on other human macrophages suggest that CD64 is a M1-like 
phenotype marker [26].  Our data suggest that the majority of our conditioning stimuli 
reduce the expression of CD64, while LPS/IFN- does not; thus if the results from out-dated 
M1 and M2 classified inducing stimuli were compared in isolation, it would appear that M1 
had increased expression of CD64, when in fact the M2 had decreased expression.  The 
increase in CD32 with the addition of IL-4 is in contrast to studies on macrophages derived 
from blood monocytes, which indicate that IL-10 but not IL-4 increases its expression [27].       
 
Few studies have investigated TIMs on THP-1 cells.  TIM-3 mRNA transcription by THP-1 
macrophages has been shown to be induced by plasma from ischemic patients [28].   This 
study is the first to show the absence of TIM-4 on either THP-1 monocytes or macrophages, 
and contrasts with human tissue macrophages such as those from spleen [29].  It is also the 
first to show TIM-1 expression on both THP-1 monocytes and macrophages and that TIM-3 
is expressed on THP-1 macrophages with expression decreased by phenotype biasing 
stimuli, similar to studies using murine macrophages [30].   
 
Of the many C-type lectin receptors we investigated, only CD69, CLEC4A, CD207, CD209, 
Dectin 1 and CD206 had previously been analyzed for expression by THP-1 cells and our data 
are broadly consistent with these reports [31-33].  The lack of expression of CD303 (BDCA-
2), CLEC4D (Dectin 3), Dectin 2, ASGPR1, CLEC9A (DNGR1), CLEC12A (MICL, CLL-1), or CD93 
and the presence of CD299 (L-SIGN), CLEC10A (CD301, MGL), CLEC13A (CD302), CD205 
(DEC-205) and KLRG1 (CLEC15A, MAFA) has not previously been reported by other studies of 
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THP-1 cells.   The alteration of CD205, CLEC4A and CLEC10A with phenotype biasing stimuli 
is also previously unreported.   
 
However, our data also contrast with certain other previous reports, albeit often using 
alternate culture conditions and maturation phenotypes.  Cermelli et al. reported CD69 was 
expressed on THP-1 monocytes [34].  We found CD207 not to be expressed by THP-1, but 
CD207 was reported from THP-1 cells differentiated into Langerhans-like cells [35].  Similarly 
Dectin 1 has been repeatedly found to be expressed at the mRNA or protein levels by THP-1 
cells in response to fungal stimulation [36, 37].  CD206, also known as mannose receptor 1 
(MRC1), which our data suggest is not expressed by THP-1 under any conditions, has been 
reported to be expressed by THP-1 cells in response to IL-4 [22, 38] or after differentiation 
to dendritic-like cells [39].  Other studies support a lack of expression of CD206 in both 
native [40] and polarized cells [41].  Compared to primary human macrophages, mRNA 
levels for MRC1 are very low [9].  CLEC4A (DCIR) has only previously been shown on tumor 
associated macrophages isolated from ovarian carcinoma [42], whereas our findings suggest 
that CLEC4A is associated with an inflammatory phenotype.  CLEC10A is well established as 
an M2-associated marker on macrophages from other sources [43], which contrasts with 
our data indicating increased expression on LPS and LPS/IFN- stimulated THP-1 
macrophages.  These discrepancies indicate caution should be practiced when considering 
the use of C-type lectin receptors as macrophage polarization markers on THP-1 cells. 
 
Signal regulatory protein beta (SIRP) has not previously been investigated on THP-1 cells, 
but has been shown to be present on human monocytes [44].  SIRP is well established as 
expressed on both THP-1 monocytes and macrophages and our data support this [45].  
Conversely, we found that SIRP expression is decreased by both LPS/IFN- and IL-4 
stimulation, in contrast to a study suggesting IL-4 increased the expression of SIRP after 48 
hours [46]. 
 
Macrophages play a key role in the progression of atherosclerotic lesions [47], as does 
intralesional hemorrhage which releases hemoglobin to the plaque interior [48].  
Hemoglobin complexed with haptoglobin is scavenged by macrophages via CD163 [49, 50], 
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resulting in the secretion of IL-10 [50].  Boyle et al. showed that monocytes differentiated 
with Hb:Hp complexes result in an atheroprotective macrophage population, which express 
high levels of CD163 and low levels of HLA-DR [4].  The lack of change in the expression of 
any markers, in particular CD163 and HLA-DR, in response to culturing with Hb:Hp suggests 
that this stimulation of THP-1 macrophages is an unrepresentative substitute for human 
blood monocyte derived macrophages in the study atherosclerosis.       
 
The markers TIM-1, CD204, CLEC4A, CLEC10A, CLEC13A and CD14 displayed heterogeneous 
expression by macrophages.  There are several potential causes of this heterogeneity.  It is 
well established that macrophages have two distinct morphologies that may also be related 
to differences in marker expression.  The macrophages may also be at different stages of 
either cell cycle or activation.  In addition, macrophages are primed to sense a constantly 
varying environment to which they respond by varying their expression of many proteins, 
including surface markers.       
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5. Conclusions 
The results presented here should provide a valuable resource for the study of human 
monocytes and macrophages by documenting the surface molecules expressed by THP-1 
cells.  Both similarities and differences between THP-1 macrophage and primary human 
monocyte derived macrophage surface expression are evident.  Our findings support the 
current view that individual markers fail to define polarization phenotypes, such as the out-
dated M1 or M2.  Moreover these subtypes are a spectrum rather than distinct and are 
characterised by many similarities as well as differences.    
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Figures 
Figure 1 
 
Figure 1. Cell Marker Expression on THP-1 Monocytes.  Filled histogram target antibody stained, 
open histogram matched isotype control.  Histograms are representative of n = 4.   
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Figure 2 
 
Figure 2. Comparison of flow cytometric cell features between THP-1 Monocytes and 
Macrophages.  A Size (FSC-A) and granularity (SSC-A) of monocytes and macrophages.    B Unstained 
monocytes (grey; +) and macrophages (black; x) shows autofluorescence within each cytometer 
channel.  Histograms and zebra plots are representative of n = 4.  GeoMean was normalised by 
subtracting the unstained value from the isotype control.  Median with IQR; Mann-Whitney tests.  
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Figure 3 
 
  
Figure 3. Cell Marker Expression on THP-1 Macrophages.  PMA differentiated THP-1 macrophages. 
Black filled histogram target antibody stained macrophages, grey filled histogram target antibody 
stained monocytes, open histogram matched isotype control macrophages.  Histograms are 
representative of n = 4.   
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Figure 4 
 
Figure 4. Comparison of Cell Marker Expression between THP-1 Monocytes and Macrophages.  
Normalized GeoMeans of markers present on both monocytes (+) and macrophages (x) compared.  
GeoMean was normalised by subtracting the matched isotype control value.  N=4; Median with IQR; 
Mann-Whitney tests.   
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Figure 5
 
 
 
Figure 5. Cell size and granularity of THP-1 Macrophages after 24 Hours Phenotype Biasing.  Size 
(FSC-A) and granularity (SSC-A) of phenotype biased macrophages, zebra plots representative of n = 
4. Median with IQR; Mann-Whitney tests. 
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Figure 6 
 
Figure 6.  Cell Marker Expression on THP-1 Macrophages after 24 Hours Phenotype Biasing.  PMA 
differentiated THP-1 macrophages after phenotype biasing for 24 hours.  No stimuli (M0) black, LPS 
red, LPS and IFN- pink, IL-4 blue, IL-1 and immune complex green, IL-10 purple, 
hemoglobin:haptoglobin orange.  GeoMean was normalised by subtracting the matched isotype 
control value.  N=4; Median with IQR; Mann-Whitney tests.   
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Figure 7 
 
Figure 7.  Percentage Positive Cell Marker Expression on THP-1 Macrophages after 24 Hours 
Phenotype Biasing.  PMA differentiated THP-1 macrophages after phenotype biasing for 24 hours.  
No stimuli (M0) black, LPS red, LPS and IFN- pink, IL-4 blue, IL-1 and immune complex green, IL-10 
purple, hemoglobin:haptoglobin orange.  Percentage positive determined by isotype control then 
normalised by subtracting the matched isotype control value.  N=4; Median with IQR; Mann-Whitney 
tests.   
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Appendices 
A.1 MIFlowCyt  
1 Overview 
1.1 Purpose: Identify the markers expressed by THP-1 monocytes and macrophages. 
1.2 Keywords: Macrophages Monocytes 
1.3 Experimental Variables: We assessed the expression of markers on untreated THP-
1 cell line monocytes, THP-1 cells differentiated with PMA to macrophages and 
THP-1 PMA macrophages with phenotypes altered with LPS, LPS and IFN-, IL-4, 
Immune complex and IL-1, IL-10 and hemoglobin:haptoglobin. N=4.    
1.4 Organisation: 
1.4.1 Name: Immunity, Infection and Inflammation, School of Medicine, Medical 
Sciences and Nutrition, University of Aberdeen 
1.4.2 Address: Institute of Medical Sciences, Foresterhill, Aberdeen, UK, AB25 2ZD 
1.5 Primary Contact: 
1.5.1 Name: Dr Megan Forrester 
1.5.2 Email Address: m.forrester@abdn.ac.uk  
1.6 Date: Experiments were performed 23/11/16 – 23/12/17; Data were analyzed 
1/2017-8/2017.    
1.7 Conclusions: Of the 49 markers tested: THP-1 monocytes express 15 (CD169, CD33, 
CD170, Siglec 10, CD32, CD64, TIM-1, CD299, CLEC10A, CLEC13A, CD205, SIRP, 
SIRP, CD13, HLA-DR), THP-1 macrophages express 28 (CD169, CD33, CD170, 
CD329, Siglec 10, CD35, CD55, CD59, CD36, CD163, CD204, CD32, CD64, TIM-1, 
TIM-3, CLEC4A, CD299, CLEC10A, CLEC13A, CD205, KLRG1, SIRP, SIRP, CD13, 
CD11b, CD11c, CD14, Mertk).  Of those 28 markers, 12 markers change their 
expression with phenotype altering stimuli (CD169, CD33, CD329, CD36, CD64, TIM-
3, CLEC4A, CLEC10A, CD205, CD11b, CD14, Mertk), along with 4 markers which 
show expression only with phenotype alteration (CD209, CD80, CD86, HLA-DR). 
1.8 Quality Control Measures: Single stain controls by staining 60 ul of Anti-Mouse or 
Anti-Rat or Anti-REA Ig CompBeads (BD#552843) and 60 ul anti-FBS negative 
control beads with 5 ul of each antibody used were used for compensation.  Non-
specific binding controlled for with manufacturer and conjugate matched isotype 
controls.  Unstained samples of monocytes and macrophages were used for each 
experiment.  N = 4.   
1.9 Other Relevant Experiment Information 
 
2 Flow Sample/Specimen Details 
2.1 Sample/Specimen Material Description: 
2.1.1 Biological Samples 
2.1.1.1 Biological Sample Description: THP-1 cell line 
2.1.1.2 Biological Sample Source Description: human peripheral blood 
2.1.1.3 Biological Sample Source Organism Description: 1 year old human male 
with acute monocytic leukemia.   
2.1.2 Environmental Samples: Not Applicable 
2.1.3 Other Samples:  Compensation beads – Mouse (BD Biosciences 552843); Rat 
(BD Biosciences 552844); REA (Miltenyi Biotec 130-104-693) 
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2.2 Sample Characteristics: Monocytes and macrophages 
2.3 Sample Treatment Description: THP-1 monocytes were kept in culture conditions 
before staining and analysis (RPMI 1640 Gibco, 20% heat inactivated FCS, penicillin, 
streptomycin and L-glutamine). THP-1 macrophages produced by PMA 1 ng/mL 
(Sigma Aldrich P1585) for four days followed by 48 hours without PMA for 
macrophages or 24 hours before stimulation for polarisation study.  They were 
seed at 5x105 cells/mL in T80cm3 flasks, 5 mL/flask two flasks per condition.  To 
alter phenotype by polarising macrophages they were stimulated for 24 hours with 
LPS (10 ng/mL; Sigma Aldrich L6529), LPS and IFN- (20 ng/mL; Miltenyi Biotec 130-
096-872), IL-4 (20 ng/mL; Miltenyi Biotec 130-095-373), IL-1 (20 ng/mL; Miltenyi 
Biotec 130-093-895) and immune complex (rabbit anti-OVA 100 µg/mL bound to 
OVA 10 µg/mL, incubated together for 30 min at 37oC; Sigma Aldrich AB1225, 
A7641), IL-10 (20 ng/mL; Miltenyi Biotec 130-093-948) or hemoglobin:haptoglobin 
complex (1:1, 100 nM; Sigma Aldrich H0267, H0138).   
Monocytes were transferred to 50 mL falcon tubes.  Flasks containing macrophages 
were placed on ice, the contents transferred into 50 mL falcon tubes and replaced 
with 5 mL ice-cold HBSS, 2 mM EDTA (Sigma Aldrich 03690) and 5% heat inactivated 
FCS.  After 10 minutes on ice the cells were gently scraped then transferred into the 
50 mL falcon tube.  The two flasks for each condition were combined.  Cells were 
then spun down and Fc block added (Human TruStain FcX; BioLegend 422302) for 
10 minutes at room temperature.   Cells were then split between mastermixes of 
antibody panels.  The untreated macrophages and monocytes were also added to 
isotype control mastermixes and kept for unstained controls.    After 30 min 
incubation with antibodies at 4oC in the dark cells were washed with cell staining 
buffer (BioLegend 420201).  Cells were then incubated for 30 min at 4oC in fixation 
buffer (Cytofix; BD Biosciences 554655).  Cells were then washed and resuspended 
in cell staining buffer and analyzed within 48 hours.    
2.4 Fluorescence Reagent(s) Description: Antibodies were split into seven panels to 
measure cell surface proteins as follows:- 
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Target 
(aka) 
Fluorochome 
Antibody Clone 
(Isotype) 
Vendor Cat# Compensation 
Isotype Control 
Cat# 
Dectin1 
(CLEC7A, CD369) 
VioBright 
FITC 
REA515 
(REA) 
Miltenyi 
Biotec 
130-107-728 
130-107-693 
Anti-REA Ig 
CompBeads 
130-104-576 
CD69 
(CLEC2C) 
BV650 
FN50 
(mIgG1) 
BioLegend 
310933 
310934 
Anti-Mouse 
CompBeads 
400164 
CD207 
(CLEC4K, Langerin) 
VioBlue 
MB22-9F5 
(mIgG1) 
Miltenyi 
Biotec 
130-106-147 
130-106-096 
Anti-Mouse 
CompBeads 
130-094-670 
CLEC12A 
(MICL, CLL-1) 
PerCP-Cy5.5 
50C1 
(mIgG2a) 
BioLegend 
353611 
353612 
Anti-Mouse 
CompBeads 
400251 
CLEC4A 
(DCIR, CD367) 
PE-Vio770 
REA329 
(REA) 
Miltenyi 
Biotec 
130-105-032 
130-104-980 
Anti-REA Ig 
CompBeads 
130-104-616 
KLRG1 
(CLEC15A, MAFA) 
PE-Vio615 
REA261 
(REA) 
Miltenyi 
Biotec 
130-108-395 
130-108-366 
Anti-REA Ig 
CompBeads 
130-107-146 
Dectin 2 
(CLEC6A) 
PE 
545943 
(mIgG1) 
RnD Systems FAB3114P 
Anti-Mouse 
CompBeads 
IC002P 
CD45 VioGreen 
5B1 
(mIgG2a) 
Miltenyi 
Biotec 
130-096-906 
THP-1 
Macrophages 
 
Appendix Table A.1 – Panel 1 Antibodies 
 
Target 
(aka) 
Fluorochome 
Antibody Clone 
(Isotype) 
Vendor Cat# Compensation 
Isotype Control 
Cat# 
ASGPR1 
(CLEC4H1) 
VioBright FITC 
REA608 
(REA) 
Miltenyi Biotec 130-109-411 
Anti-REA Ig  
CompBeads 
130-104-576 
HLA-DR BV650 
L243 
(mIgG2a) 
BioLegend 
307649 
307650 
Anti-Mouse  
CompBeads 
400265 
CLEC9A 
(DNGR-1) 
VioBlue 
8F9 
(mIgG2a) 
Miltenyi Biotec 
130-099-906 
130-097-406 
Anti-Mouse  
CompBeads 
130-098-898 
CD1a 
(HTA1, Leu-6) 
PerCP/Cy5.5 
HI149 
(mIgG1) 
BioLegend 
300129 
300130 
Anti-Mouse  
CompBeads 
400149 
CLEC13A 
(CD302) 
PE-Vio770 
REA509 
(REA) 
Miltenyi Biotec 
130-107-851 
130-107-798 
Anti-REA Ig  
CompBeads 
130-104-616 
CD303 
(BDCA-2) 
PE/Dazzle 594 
201A 
(mIgG2a) 
BioLegend 
354225 
354226 
Anti-Mouse  
CompBeads 
400275 
CLEC10A 
(CD301, MGL) 
PE 
REA586 
(REA) 
Miltenyi Biotec 
130-109-641 
130-109-582 
Anti-REA Ig  
CompBeads 
130-104-612 
CD45 VioGreen 
5B1 
(mIgG2a) 
Miltenyi Biotec 130-096-906 
THP-1  
Macrophages 
 
Appendix Table A.2 – Panel 2 Antibodies 
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Target 
(aka) 
Fluorochome 
Antibody Clone 
(Isotype) 
Vendor Cat# Compensation 
Isotype Control 
Cat# 
CD329 
(Siglec 9) 
VioBright FITC 
REA492 
(REA) 
Miltenyi Biotec 
130-107-651 
130-107-607 
Anti-REA Ig 
CompBeads 
130-104-576 
CD14 BV650 
M5E2 
(mIgG2a) 
BioLegend 
301835 
301836 
Anti-Mouse 
CompBeads 
400265 
CD328 
(Siglec 7) 
VioBlue 
REA214 
(REA) 
Miltenyi Biotec 
130-100-969 
130-100-971 
Anti-REA Ig 
CompBeads 
130-104-609 
Siglec 8 PerCP 
837535 
(mIgG1) 
RnD Systems FAB7975C 
Anti-Mouse 
CompBeads 
IC002C 
CD169 
(Siglec 1) 
PE-Vio770 
7-239 
(mIgG1) 
Miltenyi Biotec 
130-098-638 
130-098-640 
Anti-Mouse 
CompBeads 
130-096-654 
CD33 
(Siglec 3) 
PE-CF594 
WM53 
(mIgG1) 
BD Biosciences 562492 
Anti-Mouse 
CompBeads 
562292 
Siglec 10 PE 
5G6 
(mIgG1) 
Miltenyi Biotec 
130-103-730 
130-103-665 
Anti-Mouse 
CompBeads 
130-092-212 
CD45 VioGreen 
5B1 
(mIgG2a) 
Miltenyi Biotec 130-096-906 
THP-1 
Macrophages 
 
Appendix Table A.3 – Panel 3 Antibodies 
 
Target 
(aka) 
Fluorochome 
Antibody Clone 
(Isotype) 
Vendor Cat# 
Compensatio
n 
Isotype Control 
Cat# 
CD327 
(Siglec 6) 
AF488 
767329 
(mIgG1) 
RnD Systems FAB2859G 
Anti-Mouse 
CompBeads 
IC002G 
CD11b 
(CR3A, Mac-1) 
VioBlue 
M1/70.15.11.5 
(rat IgG2b) 
Miltenyi 
Biotec 
130-098-086 
130-097-336 
Anti-Rat 
CompBeads 
130-103-083 
CD16 
(FcRIII) 
PerCP-Vio770 
REA423 
(REA) 
Miltenyi 
Biotec 
130-106-766 
130-106-708 
Anti-REA Ig 
CompBeads 
130-104-620 
CD32 
(FcRII) 
PE-Cy7 
FUN-2 
(mIgG2b) 
BioLegend 
303213 
303214 
Anti-Mouse 
CompBeads 
400325 
CD64 
(FcRI) 
PE/Dazzle594 
10.1 
(mIgG1) 
BioLegend 
305031 
305032 
Anti-Mouse 
CompBeads 
400176 
CLEC4D 
(CD368, Dectin 3) 
PE 
9B9 
(mIgG2b) 
BioLegend 
360203 
360204 
Anti-Mouse 
CompBeads 
400313 
CD45 VioGreen 
5B1 
(mIgG2a) 
Miltenyi 
Biotec 
130-096-906 
THP-1 
Macrophages 
 
Appendix Table A.4 – Panel 4 Antibody Controls 
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Target 
(aka) 
Fluorochome 
Antibody Clone 
(Isotype) 
Vendor Cat# Compensation 
Isotype Control 
Cat# 
CD204 
(MSR1) 
VioBright 
FITC 
REA460 
(REA) 
Miltenyi Biotec 
130-107-063 
130-107-037 
Anti-REA Ig 
CompBeads 
130-104-576 
TIM-3 
(CD366, HAVCR2) 
BV650 
F38-2E2 
(mIgG1) 
BioLegend 
345027 
345028 
Anti-Mouse 
CompBeads 
400164 
CD59 
(MIRL) 
BV421 
P282 (H19) 
(mIgG2a) 
BD Biosciences 
565982 
564329 
Anti-Mouse 
CompBeads 
562439 
CD36 
(GP4) 
PerCP 
AC106 
(mIgG2a) 
Miltenyi Biotec 130-095-480 
Anti-Mouse 
CompBeads 
130-099-190 
CD55 
(CR, DAF) 
PerCP/Cy5.5 
JS11 
(mIgG1) 
BioLegend 
311315 
311316 
Anti-Mouse 
CompBeads 
400149 
TIM-1 
(CD365, HAVCR) 
PE-Vio770 
REA692 
(REA) 
Miltenyi Biotec 
130-106-075 
130-106-026 
Anti-REA Ig 
CompBeads 
130-104-616 
CD163 PE/Dazzle594 
GHI/61 
(mIgG1) 
BioLegend 
333623 
333624 
Anti-Mouse 
CompBeads 
400176 
TIM-4 PE 
9F4 
(mIgG1) 
BioLegend 354004 
Anti-Mouse 
CompBeads 
400113 
CD45 VioGreen 
5B1 
(mIgG2a) 
Miltenyi Biotec 130-096-906 
THP-1 
Macrophages 
 
Appendix Table A.5 – Panel 5 Antibodies 
 
Target 
(aka) 
Fluorochome 
Antibody 
Clone 
(Isotype) 
Vendor Cat# Compensation 
SIRP 
(CD172a) 
FITC 
REA490  
(REA) 
Miltenyi Biotec 
130-099-897 
130-099-896 
Anti-REA Ig  
CompBeads 
CD86 
(B7.2) 
BV650 
IT2.2 
(mIgG2b) 
BioLegend 
305427 
305428 
Anti-Mouse  
CompBeads 
CD80 
(B7.1) 
BV421 
L307.4 
(mIgG1) 
BD Biosciences 
566263 
564160 
Anti-Mouse  
CompBeads 
CD209 
(DC-SIGN) 
PerCP-Vio770 
REA617 
(REA) 
Miltenyi Biotec 
130-109-652 
130-109-593 
Anti-REA Ig  
CompBeads 
SIRP 
(CD172b) 
PE-Vio770 
B4B6 
(mIgG1) 
Miltenyi Biotec 
130-105-311 
130-105-269 
Anti-Mouse  
CompBeads 
CD206 
(MRC1, CLEC13D) 
PE/Dazzle594 
15-2 
(mIgG1) 
BioLegend 
321129 
321130 
Anti-Mouse  
CompBeads 
CD205 
(CLEC13B, DEC-205) 
PE 
HD30  
(mIgG1) 
Miltenyi Biotec 130-096-369 
Anti-Mouse  
CompBeads 
CD45 VioGreen 
5B1  
(mIgG2a) 
Miltenyi Biotec 130-096-906 
THP-1  
Macrophages 
Appendix Table A.6 – Panel 6 Antibodies 
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Target 
(aka) 
Fluorochome 
Antibody Clone 
(Isotype) 
Vendor Cat# 
Compensatio
n 
Isotype 
Control  
Cat# 
CD93 
(C1QR1) 
FITC 
VIMD2 
(mIgG1) 
Miltenyi Biotec 130-098-431 
Anti-Mouse 
CompBeads 
130-092-213 
CD11c 
(CR4) 
BV650 
3.9 
(mIgG1) 
BioLegend 
301637 
301638 
Anti-Mouse 
CompBeads 
400164 
Mertk BV421 
590H11G1E3 
(mIgG1) 
BioLegend 
367603 
367604 
Anti-Mouse 
CompBeads 
400157 
CD35 
(CR1) 
PerCP-Vio770 
E11 
(mIgG1) 
Miltenyi Biotec 
130-101-618 
130-101-612 
Anti-Mouse 
CompBeads 
130-097-561 
CD170 
(Siglec 5) 
PE-Vio770 
1A5 
(mIgG1) 
Miltenyi Biotec 
130-101-794 
130-101-772 
Anti-Mouse 
CompBeads 
130-096-654 
CD13 
(gp150, LAP1) 
PE/Dazzle594 
WM15 
(mIgG1) 
BioLegend 
301719 
301720 
Anti-Mouse 
CompBeads 
400176 
CD299 
(L-SIGN, CLEC4M) 
PE 
REA587 
(REA) 
Miltenyi Biotec 
130-109-299 
130-109-221 
Anti-REA Ig 
CompBeads 
130-104-612 
CD45 VioGreen 
5B1 
(mIgG2a) 
Miltenyi Biotec 130-096-906 
THP-1 
Macrophages 
 
Appendix Table A.7 – Panel 7 Antibodies 
   
3 Instrument Details: 
3.1 Instrument Manufacturer: Becton Dickinson 
3.2 Instrument Model: LSR Fortessa 5 Laser Blue, Red, Yellow/Green, Violet, UV 
3.3 Instrument Configuration and Settings 
 
Laser 
BP 
Filter 
LP 
Mirror 
Parameter Detected 
Detector 
Voltage 
UV 
(355nm) 
530/30 505 - - 
450/50 - - - 
Violet 
(405nm) 
655/8 630 Brilliant Violet 650 405 
605/12 595 - - 
585/15 575 - - 
525/50 505 VioGreen 250 
450/50 - VioBlue; Brilliant Violet 421 215 
Blue 
(488nm) 
695/40 685 PerCP-Cy5.5; PerCP-Vio700 405 
670/14 635 PerCP 405 
530/30 505 FITC; Alexa Fluor 488; VioBright FITC 330 
488/10 - SSC 170 
Yellow 
/Green 
(561nm) 
780/60 750 PE-Cy7; PE-Vio770 555 
710/50 685 - - 
660/20 635 - - 
610/20 600 PE-CF594; PE-Dazzle594; PE-Vio615 455 
585/15 570 PE 435 
Red 
(640nm) 
780/60 755 - - 
730/45 685 - - 
670/14 - Cell Trace Far Red – Not Used In This Study 385 
Appendix Table A.8 – Cytometer Laser and Filter Settings 
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4 Data Analysis Details 
4.1 List-mode Data File 
4.2 Compensation Details 
4.2.1 Compensation Description: Compensation matrices for each panel were 
created using single stained compensation beads and THP-1 macrophages stained 
for CD45 VioGreen and unstained macrophages acquired and generated by the Diva 
software.  Post-acquisition compensation matrices were adjusted using FlowJoX.  
The matrices for each panel are as follows:- 
 
Panel 01 VioBright FITC PerCP-Cy5.5 APC VioBlue VioGreen BV650 PE PE-Vio615 PE-Vio770 
VioBright FITC - Dectin 
1 
- 2.7763 0 0 0.0765 0 0 0 0 
PerCP-Cy5.5 - CLEC122A 0 - 7.8074 0 0 0 0 0 35.9332 
APC - CTFR RBC 0.5199 1.3549 - 0.2299 0.3679 19.6969 0.0085 1.0134 10.9597 
VioBue - CD207 0 0 0 - 0 0 0 0 0 
VioGreen - CD45 0 0 0 6.3492 - 413.1746 0 0 0 
BV650 - CD69 0 0 6.5302 0 0 - 0 0 0 
PE - Dectin 2 0 2.2546 0 0 0 0 - 34.1136 0.9557 
PE-Vio615 - KLRG1 0 28.6593 0.1612 0 0 5.9552 21.3943 - 23.909 
PE-Vio770 - CLEC4A 0 0 0 0 0 0 0.5654 0.1489 - 
Appendix Table A.9 - Panel 01 Compensation Matrix 
 
Panel 02 VioBright FITC PerCP-Cy5.5 APC VioBlue VioGreen BV650 PE PE-Dazzle 594 PE-Vio770 
VioBright FITC - 
ASGPR1 
- 0 0 0 0 0 0 0 0 
PerCP-Cy5.5 - CD1a 0 - 7.7963 0 0 0 0 0 35.882 
APC - CTFR RBC 0.3665 1.703 - 0.2517 0.2307 17.3457 0 1.8644 9.788 
VioBlue - CLEC9A 0 0 0 - 0 0 0 0 0 
VioGreen - CD45 0 0 0.4884 6.8017 - 43.1259 0 0 0 
BV650 - HLA-DR 0 0 6.6389 0 0 - 0 0 0 
PE - CLEC10A 0.013 3.1762 0 0 0 0.644 - 34.1131 1.882 
PE-Dazzle 594 - CD303 0 14.1603 0 0 0 0.6112 21.4063 - 9.8896 
PE-Vio770 - CLEC13A 0 0 0 0 0 0 0.4712 0.1104 - 
Appendix Table A.10 - Panel 02 Compensation Matrix 
 
Panel 03 VioBright FITC PerCP APC VioBlue VioGreen BV650 PE PE-CF594 PE-Vio770 
VioBright FITC - CD329 - 6.0342 0 0 0 0 4.0953 0 0 
PerCP - Siglec 8 0 - 8.3246 0 0 0 0 0 0.6997 
APC - CTFR RBC 0.6069 2.4276 - 0.5558 0.7642 17.7674 0.3474 13.122 9.726 
VioBlue - CD328 0 0 0 - 18.4556 0 0 0 0 
VioGreen - CD45 0 0 0.7315 5.0715 - 41.3524 0 0 0 
BV650 - CD14 0 0 6.8805 0 0 - 0 0 1.191 
PE - Siglec 10 0 4.6714 0 0 0 0 - 34.1258 1.3566 
PE-CF594 - CD33 0 27.6293 0 0 0 0.9175 19.0975 - 13.4022 
PE-Vio770 - CD169 0 0 0 0 0 0 0.5984 0.0361 - 
Appendix Table A.11 - Panel 03 Compensation Matrix 
 
Panel 04 AF488 APC VioBlue VioGreen PE PE-Dazzle594 PE-Cy7 PerCP-Vio770 
AF488 - CD327 - 0 0 0.1494 5.6821 0.5535 0 2.901 
APC - CTFR RBC 1.1908 - 0.5444 1.2563 0.791 2.5901 11.5082 2.8262 
VioBlue - CD11b 0 0 - 0 0 0 0 0 
VioGreen - CD45 1.5403 0.3065 7.7657 - 1.3624 3.0276 0.9083 1.5403 
PE - CLEC4D 0 0 0 0 - 32.5272 1.4754 2.6705 
PE-Dazzle 594 - CD64 0 0 0 0 26.7822 - 10.1196 14.3176 
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PE-Cy7 - CD32 0 0 0 0 0.3235 0 - 0 
PerCP-Vio770 - CD16 0 4.3536 0 0 0 0 46.6628 - 
Appendix Table A.12 - Panel 04 Compensation Matrix 
 
Panel 05 VioBright FITC PerCP PerCP-Cy5.5 APC BV421 
VioGree
n 
BV650 PE PE-Dazzle 594 PE-Vio770 
VioBright FITC - CD204 - 
10.829
9 
4.0478 0 0 0.9456 0 0 0 0 
PerCP - CD36 0 - 17.7778 
7.145
3 
0 0 0 0 0 0 
PerCP-Cy5.5 - CD55 0 
75.695
5 
- 
7.532
3 
0 0 0 0 0 34.6642 
APC - CTFR RBC 0.4298 3.2457 1.464 - 
0.351
6 
0.7092 
18.329
4 
0.498
4 
0.9967 9.8664 
BV421 - CD59 0 0 0 0 - 1.9565 0 0 0 0 
VioGreen - CD45 0.2728 2.7962 1.4322 0 
8.427
3 
- 
43.596
6 
1.253
4 
0 0.8848 
BV650 - TIM-3 0 0 0 
6.852
8 
0 0 - 0 0 0.6392 
PE - TIM-4 0 5.6278 2.6001 0 0 0 0 - 33.0307 1.3133 
PE-Dazzle 594 - CD163 0 
29.973
9 
14.2005 0 0 0 0.8963 
21.78
9 
- 10.1111 
PE-Vio770 - TIM-1 0 0 0 0 0 0 0 
0.832
6 
0.2109 - 
Appendix Table A.13 - Panel 05 Compensation Matrix 
 
Panel 06 FITC PerCP-Vio770 APC BV421 VioGreen BV650 PE PE-Dazzle 594 PE-Vio770 
FITC - SIRPa  0 0 0 0.7664 0 0 0 0 
PerCP-Vio770 - CD209 0  1.1694 0 0 0 0 0 41.118 
APC - CTFR RBC 0.7367 1.9189  0.6069 1.0809 19.3754 0.6808 1.1047 10.7706 
BV421 - CD80 0 0 0  0.6891 0 0 0 0 
VioGreen - CD45 1.963 2.0751 0.5344 13.5392  49.0499 1.0557 0 1.0557 
BV650 - CD86 0 0 6.0436 0 0  0 0 0 
PE - CD205 0 2.3872 0 0 0 0.1066  33.9494 1.4026 
PE-Dazzle 594 - CD206 0 14.1075 0 0 0 1.0176 20.8554  10.0037 
PE-Vio770 - SIRPb 0 0 0 0 0 0 0.4053 0  
Appendix Table A.14 - Panel 06 Compensation Matrix 
 
Panel 07 FITC PerCP-Vio770 APC BV421 VioGreen BV650 PE PE-Dazzle 594 PE-Vio770 
FITC - CD93  0 0 0 0 0 0 0 0 
PerCP-Vio770 - CD35 0  1.8533 0 0 0 0 0 41.4128 
APC - CTFR RBC 0.8421 2.3468  0.2418 0.9805 19.2875 0.5223 0.7014 11.2674 
BV421 - Mertk 0 0 0  2.3082 0 0 0 0 
VioGreen -CD45 1.7246 0.8277 0 11.0067  45.9732 0 0 0 
BV650 - CD11c 0 0.4637 7.0781 0.7212 0  0 0.5661 3.6011 
PE - CD299 0 2.6319 0 0 0 0.2336  34.3699 1.192 
PE-Dazzle 594 - CD13 0 14.342 0 0 0 1.1192 20.3993  10.1312 
PE-Vio770 - CD170 0 0 0 0 0 0 0.8492 0  
Appendix Table A.15 - Panel 07 Compensation Matrix 
 
4.2.2 Compensation Information 
4.3 Data Transformation Details: 
4.3.1 Purpose of Data Transformation: To visualise events against the axis better 
and to account for non-specific binding and autofluorescence. 
4.3.2 Data Transformation Description: Bi-exponential transformation was used.   
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4.3.3 Other Relevant Data Transformation Details:  GeoMean was normalised by 
subtracting the matched isotype control value.  For binding GeoMean was 
normalised by subtracting the unstained value from the isotype control.   
4.4 Gating Details 
4.4.1 Gate Description:  Cells were first gated to eliminate debris (FSC-A vs SSC-A) 
then gated for single cells (SSC-A vs SSC-W).   
4.4.2 Gate Statistics: Monocytes: Cells average 87.4% single cells: 93.6%.  
Macrophages: Cells average 67.1% single cells average 85.4%  
4.4.3 Gate Boundaries:
 
4.4.4 Other Relevant Gate Information 
 
A viability dye was not used in these experiments but it was confirmed that the culturing 
conditions, staining protocol and gating strategy resulted in dead cells comprising less than 
2% of the cells analyzed.    
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Fig B.1 
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Figure B.1. Cell Marker Expression on THP-1 Monocytes, Macrophages and After 24 Hours 
Phenotype Biasing.  Unstimulated THP-1 monocytes (+), PMA differentiated (M0) macrophages (x) 
compared to phenotype biased for 24 hours.  No stimuli black, LPS red, LPS and IFN- pink, IL-4 blue, 
IL-1 and immune complex green, IL-10 purple, hemoglobin:haptoglobin orange.  N=4; Median with 
IQR; Mann-Whitney tests.   
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Similarities and differences in surface receptor expression by THP-1 
monocytes and differentiated macrophages polarized using seven different 
conditioning regimens 
Authors: 
Megan A. Forrestera, Heather J. Wassalla, Huan Caoa, Heather M. Wilsona, Robert N. 
Barkera and Mark A. Vickersa,b  
 
 
Highlights 
 
 Human cell line THP-1 monocytes expressed 14 of 49 surface markers 
examined     
 THP-1 differentiated macrophages expressed a wider repertoire of 
receptors (34) 
 Differentially polarized macrophages displayed unexpectedly similar 
receptors  
 Some markers (9) changed specifically to the polarizing stimuli 
 
 
 
